Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 5:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 802 matching trials from the live ClinicalTrials.gov search.
Conditions
Chronic Low-back Pain
Interventions
Mindfulness-based dance/movement therapy (M-DMT), Chronic pain social support group
Behavioral
Lead sponsor
Drexel University
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Adult Anaplastic Astrocytoma, Adult Anaplastic Ependymoma, Adult Anaplastic Oligodendroglioma, Adult Diffuse Astrocytoma, Adult Ependymoma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Mixed Glioma, Adult Myxopapillary Ependymoma, Adult Oligodendroglioma, Adult Pilocytic Astrocytoma, Adult Pineal Gland Astrocytoma, Adult Subependymoma
Interventions
etanidazole, conventional surgery, pharmacological study, laboratory biomarker analysis
Drug · Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Subcutaneous Bupivacaine Decrease Post-op Pain in Patients Undergoing C-Section

NCT03383588
Conditions
Pain, Referred
Interventions
Bupivacaine, Morphine, Fentanyl, Epinephrine, Saline solution
Drug · Other
Lead sponsor
Montefiore Medical Center
Other
Eligibility
17 Years to 40 Years · Female only
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
The Bronx, New York
Completed Not applicable Interventional

Facilitating Optimal Routines in Aging

NCT03913637
Conditions
Mild Cognitive Impairment
Interventions
Strategy Training, Enhanced Usual Care
Behavioral · Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
60 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Atomoxetine, Placebo, Parent Training
Drug · Behavioral
Lead sponsor
University of Nebraska
Other
Eligibility
5 Years to 6 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
3
States / cities
Omaha, Nebraska • New York, New York • Durham, North Carolina
Conditions
Suicide, Psychiatric Rehabilitation
Interventions
ACT for Life, Treatment as usual
Behavioral · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 89 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Aurora, Colorado
Completed Not applicable Interventional Accepts healthy volunteers

Validating Cardiac MRI Biomarkers and Genotype-Phenotype Correlations for DMD

NCT02834650
Conditions
Muscular Dystrophy, Duchenne
Interventions
Cardiac MRI with contrast, Cardiac MRI without contrast, Blood Test, Heart Rate, Pulmonary Function Test, Genetic Testing, Repeat MRI scan
Other
Lead sponsor
Stanford University
Other
Eligibility
7 Years to 21 Years · Male only
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
3
States / cities
Los Angeles, California • Orange, California • Stanford, California
Completed Not applicable Interventional

Opioid-Free Orthopaedic Surgery

NCT04176783
Conditions
Pain Management
Interventions
Opioids, Opioid-Free
Drug
Lead sponsor
OrthoCarolina Research Institute, Inc.
Other
Eligibility
18 Years and older
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Charlotte, North Carolina
Conditions
Prostate Cancer
Interventions
Androgen Deprivation Therapy (ADT), Focal prostate ablation (focal therapy)
Drug · Procedure
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older · Male only
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
AMPD3, OMIM*102772, AMP Deaminase Deficiency, AK1, OMIM *103000, Adenylate Kinase Deficiency, AMPD1, OMIM *102770, Myopathy Due to Myoadenylate Deaminase Deficiency, TPMT, OMIM *187680, Thoipurines, Poor Metabolism of, IMPDH1, OMIM *146690, Retinitis Pigmentosa Type 10, Leber Congenital Amauriosis Type 11, APRT, OMIM *102600, Adenine Phosphoribosyltransferase Deficiency, HPRT1, OMIM *308000 Lesch-Nyhan Disease, XDH, OMIM *607633, Xanthinuria Type 1, SLC2A9, OMIM *606142 Hypouricemia, SLC22A12, OMIM *607096 Hypouricemia, PRPS1 Def, OMIM *311850, Arts Syndrome; Charcot-Marie-Tooth Disease, PRPS1 SA, OMIM *311850 Gout, PRPS-related Phosphoribosylpyrophosphate Synthetase Superactivity, AMPD2, OMIM *102771, Spastic Paraplegia 63; Pontocerebellar Hypoplasia, ITPA, OMIM *147520, Inosine Triphosphatase Deficiency; Developmental and Epileptic Encephalopathy 35, ADSL, OMIM *608222, Adenylosuccinate Lyase Deficiency, PNP, OMIM *164050, Nucleoside Phosphorylase Deficiency, ADA2, OMIM *607575,Sneddon Syndrome; VAIHS, CAD, *1140120, Developmental and Epileptic Encephalopathy, UPB1, OMIM *606673, Beta-ureidopropionase Deficiency, DPYS, OMIM *613326, Dihydropyrimidinase Deficiency, DPYD, OMIM *274270, Dihydropyrimidine Dehydrogenase Deficiency, DHODH, OMIM *126064, Miller Syndrome (Postaxial Acrofacial Dysostosis), UMPS, OMIM *613891, Orotic Aciduria, NT5C3A<TAB>, OMIM *606224, Anemia, Hemolytic, Due to UMPH1 Deficiency, UNG, OMIM *191525, Hyper-IgM Syndrome 5, AICDA, OMIM *605257, Immunodeficiency With Hyper-IgM, Type 2; HIGM2, Purine-Pyrimidine Metabolism, Metabolic Disease
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
1 Month to 100 Years
Enrollment
999 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2099
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Kidney Cancer
Interventions
motexafin gadolinium, sunitinib malate, comparative genomic hybridization, gene expression analysis, mutation analysis, polymorphism analysis, immunohistochemistry staining method, iodine I-124 girentuximab, laboratory biomarker analysis, pharmacological study, adjuvant therapy, neoadjuvant therapy, therapeutic conventional surgery
Drug · Genetic · Other + 1 more
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Active, not recruiting Not applicable Interventional

Dried Plums and Bone Health in Postmenopausal Women

NCT02822378
Conditions
Postmenopausal Osteoporosis
Interventions
Dried Plum, Calcium supplement, Vitamin D supplement
Dietary Supplement
Lead sponsor
Penn State University
Other
Eligibility
55 Years to 75 Years · Female only
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
University Park, Pennsylvania
Conditions
Endometrial Hyperplasia, Grade 1 Endometrial Cancer
Interventions
Telemedicine behavioral weight intervention, Progestin, Enhanced usual care, Levonorgestrel-releasing IUD.
Behavioral · Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
3
States / cities
St Louis, Missouri • Albuquerque, New Mexico • Oklahoma City, Oklahoma
Conditions
Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Neurotoxicity Syndrome, Pain, Regional Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma
Interventions
Cytology Specimen Collection Procedure, Pharmacological Study
Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 15 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Appendicitis
Interventions
Operative management, Drainage or antibiotics
Procedure · Other
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Gaucher Disease
Interventions
Blood sample
Procedure
Lead sponsor
Amicus Therapeutics
Industry
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
7
States / cities
San Francisco, California • Coral Springs, Florida • Decatur, Georgia + 4 more
Conditions
Carcinoma, Small Cell, Lung Cancer, Small Cell Lung Cancer
Interventions
M7824, Topotecan, Temozolomide, EKG, CT scan, PET scan, Acetaminophen, Antihistamines, Diphenhydramine, Dexamethasone, Epinephrine
Drug · Diagnostic Test
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Acute Decompensated Heart Failure
Interventions
loop diuretic, tolvaptan, ultrafiltration
Drug · Procedure
Lead sponsor
The Christ Hospital
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Blood Loss, Surgical, Coagulation Disorder
Interventions
VMX-C001, Usual Pharmacological Care
Drug
Lead sponsor
VarmX B.V.
Industry
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
17
States / cities
Chandler, Arizona • Phoenix, Arizona • Stanford, California + 12 more
Conditions
Traumatic Brain Injury
Interventions
Global Z-Score Neurofeedback Training
Behavioral
Lead sponsor
The Defense and Veterans Brain Injury Center
Federal
Eligibility
18 Years to 50 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
1
States / cities
Fort Carson, Colorado
Conditions
Dementia, Dementia, Vascular, Alzheimer Disease, Dementia, Mixed
Interventions
The BRAIN App
Behavioral
Lead sponsor
Hopeful Aging
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Winchester, Massachusetts
Conditions
Venothromboembolism
Interventions
Risk model-driven CDS
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
Not listed
Enrollment
2,236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Conditions
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Echocardiography, Fludarabine, Fludeoxyglucose F-18, Immunotherapy, Leukapheresis, Magnetic Resonance Imaging, Positron Emission Tomography
Procedure · Drug · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years to 74 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Absence of Signs or Symptoms, B-Cell Non-Hodgkin Lymphoma, Digestive System Signs and Symptoms, Indolent Adult Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Indolent Adult Non-Hodgkin Lymphoma, Recurrent Small Lymphocytic Lymphoma
Interventions
Biospecimen Collection, Colonoscopy, Colposcopic Biopsy, Idelalisib, Laboratory Biomarker Analysis, Pharmacological Study, Physical Examination, Sigmoidoscopy
Procedure · Drug · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Los Angeles, California